Important Notices
Notice (21/03/2025):
Due to supply issues at the company who provide our inherited cancer panel assay (including NF1 and NF2 referrals) there may be delays of around 2-4 weeks in issuing reports. We are working to resolve the situation and minimise delays as much as possible. Thank you for your patience and understanding as we work to resolve this issue
Notice(02/01/2025):
An updated version of the Rare and Inherited Disease National Genomic Test Directory was published on 2nd January 2025 (version 7.1).
Please refer to a copy of our user communication letter for a summary of the main changes.
To enable transition to this new specification, any referrals received by the North West Genomic Laboratory Hub (NW GLH) before Monday 3rd February will continue to be processed in accordance with the previous National Genomic Test Directory (version 7).
Any samples received from 3rd February must fulfil the new TD requirements in order for testing to be initiated.
If you have any queries about these test directory changes please contact mft.genomic@nhs.net
The North West Genomic Laboratory Hub (GLH) is one of a network of seven GLHs across the country, which together forms the new national Genomic Medicine Service. Each GLH is responsible for coordinating services for a particular part of the country.
The NW GLH has been implementing several quality improvements to align systems across the Liverpool and Manchester laboratory sites. Currently, we are rolling out a new standardised report style for services delivered by the NW GLH to improve consistency and uniformity of the information provided on our reports. Please note that the UKAS accreditation symbol does not feature on the report; it is displayed on our website (under ‘Accreditation’) along with relevant links to our schedule of accreditation. If you have any comments or queries regarding the new style of reports, please contact us.
